LISTING OF CLAIMS:

This listing of claims provided below will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method for treating a host infected with a *togavirus* or a *coronavirus* ~~or a herpes virus,~~ comprising administering an anti-viral effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, having a structure of Formula I:

(I)



wherein: R_1 is —NHC(O)Y, where Y is C_1-C_{22} alkyl, C_2-C_{22} alkenyl, or C_2-C_{22} alkynyl;
R_2 is —OX, where X is C_1-C_{22} alkyl, C_2-C_{22} alkenyl, C_2-C_{22} alkynyl; and
R_3 is phosphocholine;
optionally with a pharmaceutically acceptable carrier or diluent.

2. (Withdrawn) The method of claim 1, wherein
Y is C_1-C_{14} alkyl, C_2-C_{14} alkenyl, or C_2-C_{14} alkynyl; and
X is C_1-C_{14} alkyl, C_2-C_{14} alkenyl, or C_2-C_{14} alkynyl.

3. (Withdrawn) The method of claim 1 wherein:
Y is —$C_{11}H_{23}$, —$C_{10}H_{21}$ or —C_9H_{19}; and
X is —CH_2CH_3, —$(CH_2)_2CH_3$, —$(CH_2)_3CH_3$, or —$CH_{10}CH_{21}$.

4. (Withdrawn) The method of claim 1, wherein Y is —$C_{11}H_{23}$ and X is C_1-C_5 alkyl.

5. (Withdrawn) The method of claim 1, wherein Y is —C_9H_{19} and X is C_9-C_{11} alkyl.

6. (Withdrawn) The method of claim 1, wherein the compound is:



3-dodecanamido-2-ethoxypropyl-1-phosphocholine;



3-decanamido-2-ethoxypropyl-1-phosphocholine;



3-decanamido-2-decyloxypropyl-1-phosphocholine;



3-dodecanamido-2-octyloxypropyl-1-phosphocholine;



3-dodecanamido-2-dodecyloxy-1-phosphocholine; or



3-dodecanamido-2-butyloxypropyl-1-phosphocholine;

or a combination thereof.

7. (Previously presented) The method of claim 1, wherein the virus is a *coronavirus*.

8. (Previously presented) The method of claim 7, wherein the *coronavirus* is SARS-CoV.

Claims 9-11. (Cancelled).

12. (Previously presented) The method of claim 1, wherein the host is a mammal.

13. (Previously presented) The method of claim 1, wherein the host is a human.

14. (Withdrawn) A method for treating a host infected with a *togavirus*, herpes virus or *coronavirus*, comprising administering an anti-viral effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, having a structure of Formula II:

(II)



wherein:

M is C_2-C_4 alkyl;

X_1 is —S—, —O—, —NH—, or —NHC(O)—;

R_{21} is —C_1-C_{20} straight chain alkyl, —C_2-C_{20} straight chain alkylene containing not more than four double bonds, or aryl;

R_{22} is —C_1-C_{20} straight chain alkyl, —C_2-C_{20} straight chain alkylene containing not more than four double bonds, or aryl; and

R_{23}, R_{24}, and R_{25} are each independently either hydrogen, methyl, ethyl, propyl, or isopropyl;

optionally with a pharmaceutically acceptable carrier or diluent.

15. (Withdrawn) The method of claim 14 wherein:

M is —CH_2CH_2—;

X_1 is —S—, —O—, —NH—, or —NHC(O)—;

R_{21} is C_1-C_{16} straight chain alkyl, or —C_2-C_{16} straight chain alkylene containing not more than one double bond;

R_{22} is C_1-C_{16} straight chain alkyl, or —C_2-C_{16} straight chain alkylene containing not more than one double bond; and

R_{23}, R_{24}, and R_{25} are each independently hydrogen or methyl.

16. (Withdrawn) The method of claim 14 wherein:

R_{22} is C_1-C_5 straight chain alkyl, or —C_2-C_5 straight chain alkylene containing not more than one double bond.

17. (Withdrawn) The method of claim 15, wherein R21 is —C_9-C_{12} alkyl, and R_{22} is —C_1-C_{12} alkyl.

18. (Withdrawn) The method of claim 15, wherein R_{21} is —C_9-C_{12} alkyl, and R_{22} is —C_1-C_5 alkyl.

19. (Withdrawn) The method of claim 15, wherein R_{21} is —C_9-C_{12} alkyl, and R_{22} is —C_8-C_{12} alkyl.

20. (Withdrawn) The method of claim 14, wherein the virus is a *coronavirus*.

21. (Withdrawn) The method of claim 20, wherein the *coronavirus* is SARS-CoV.

22. (Withdrawn) The method of claim 14, wherein the virus is a herpes virus.

23. (Withdrawn) The method of claim 22, wherein the herpes virus is varicella zoster virus.

24. (Withdrawn) The method of claim 22, wherein the herpes virus is *cytomegalovirus*.

25. (Withdrawn) The method of claim 14, wherein the host is a mammal.

26. (Withdrawn) The method of claim 14, wherein the host is a human.

27. (Withdrawn) A method for treating a host infected with a *togavirus*, herpes virus or *coronavirus* comprising administering an anti-viral effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, having a structure of Formula III:

(III)



wherein:

Y is —S—, —O—, —NH—, —N(CH_3)—, —NHC(O)—, or —N(CH_3)C(O)—;

R_1 is C_1-C_{18} alkyl, C_2-C_{18} alkenyl, C_2-C_{18} alkynyl or aryl;

X is a covalent bond or methylene that is optionally substituted with hydroxyl, C_1-C_{20} alkyl, —O—(C_1-C_{20} alkyl), —S—(C_1-C_{20} alkyl), —(C(O)N(C_1-C_{20} alkyl), C_2-C_{20} alkenyl, —O—(C_2-C_{20} alkenyl), —S—(C_2-C_{20} alkenyl), —(C(O)N(C_2-C_{20} alkenyl), C_2-C_{20} alkynyl, —O—(C_2-C_{20} alkynyl), —S—(C_2-C_{20} alkynyl) or —(C(O)N(C_2-C_{20} alkynyl);

J is C_1-C_4 alkyl optionally substituted one to three times with methyl or ethyl; and

R_2, R_3, and R^4 are H or C_1-C_3 alkyl;

optionally with a pharmaceutically acceptable carrier or diluent.

28. (Withdrawn) The method of claim 27 wherein: Y is —NHC(O)—; R_1 is —C_6-C_{18} alkyl; X is —CH—O—(C_1-C_{18} alkyl) or —CH—O—(C_1-C_{18} alkenyl); J is —CH_2CH_2—; and R_2, R_3, and R_4 are each methyl.

29. (Withdrawn) The method of claim 28, wherein X is —CH—O—(C_1-C_5 alkyl) or —CH—O—(C_2-C_5 alkenyl).

30. (Withdrawn) The method of claim 28, wherein R_1 is —C_8-C_{12} alkyl and X is —CH—O—(C_1-C_5 alkyl) or —CH—O—(C_2-C_5 alkenyl).

31. (Withdrawn) The method of claim 28, wherein R_1 is —C_8-C_{12} alkyl and X is —CH—O—(C_8-C_{12} alkyl) or —CH—O—(C_8-C_{12} alkenyl).

32. (Withdrawn) The method of claim 27, wherein the virus is a *coronavirus*.

33. (Withdrawn) The method of claim 32, wherein the *coronavirus* is SARS-CoV.

34. (Withdrawn) The method of claim 27, wherein the virus is a herpes virus.

35. (Withdrawn) The method of claim 34, wherein the herpes virus is varicella zoster virus.

36. (Withdrawn) The method of claim 34, wherein the herpes virus is *cytomegalovirus*.

37. (Withdrawn) The method of claim 27, wherein the host is a mammal.

38. (Withdrawn) The method of claim 27, wherein the host is a human.

39. (Withdrawn) A method for treating a host infected with a *coronavirus*, herpes virus or *togavirus*, comprising administering an anti-viral effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, having a structure of Formula IV:

(IV)



wherein:

R_1 is a C_6-C_{18} alkyl, C_6-C_{18} alkenyl, or C_6-C_{18} alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;

X is —NHC(O)—, —$N(CH_3)$C(O)—, —C(O)NH—, —C(O)$N(CH_3)$—, —S—, —S(O)—, —(SO_2)—, —O—, —NH—, and —$N(CH_3)$—;

R_2 is a C_1-C_{14} alkyl, C_2-C_{14} alkenyl, or C_2-C_{14} alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;

Y is —NHC(O)—, —$N(CH_3)$C(O)—, —C(O)NH—, —C(O)$N(CH_3)$—, —S—, —S(O)—, —(SO_2)—, —O—, —NH—, —$N(CH_3)$—, or —OC(O)—;

R_6 is a C_2-C_6 alkyl; C_2-C_6 alkenyl, or C_2-C_6 alkynyl; and

R_3, R_4, and R_5 are independently methyl or ethyl, or R_3 and R^4 together form an aliphatic or heterocyclic ring having five or six ring atoms and R_5 is methyl or ethyl;

optionally with a pharmaceutically acceptable carrier or diluent.

40. (Withdrawn) The method of claim 39 wherein

R_2 is C_1-C_{14} alkyl, C_2-C_{14} alkenyl, or C_2-C_{14} alkenyl;

R^6 is CH_2CH2; and R_3, R_4, and R_5 are each independently CH_3.

41. (Withdrawn) The method of claim 40, wherein R_2 is —C_1-C_5 alkyl or —C_1-C_5 alkenyl.

42. (Withdrawn) The method of claim 40, wherein R_1 is —C_8-C_{12} alkyl and R_2 is —C_8-C_{12} alkyl.

43. (Withdrawn) The method of claim 40, wherein R_1 is —C_8-C_{12} alkyl and R_2 is —C_1-C_5 alkyl.

44. (Withdrawn) The method of claim 40, wherein R^1 is —C_8-C_{12} alkyl and R_2 is —C_8-C_{12} alkyl.

45. (Withdrawn) The method of claim 39, wherein: X is —NHC(O)—, —$N(CH_3)$C(O)—, —C(O)NH—, or —C(O)$N(CH_3)$—; and Y is —O—, —NH—, or —$N(CH_3)$—.

46. (Withdrawn) The method of claim 39, wherein the virus is a *coronavirus*.

47. (Withdrawn) The method of claim 46, wherein the *coronavirus* is SARS-CoV.

48. (Withdrawn) The method of claim 39, wherein the virus is a herpes virus.

49. (Withdrawn) The method of claim 48, wherein the herpes virus is varicella zoster virus.

50. (Withdrawn) The method of claim 47, wherein the herpes virus is *cytomegalovirus*.

51. (Withdrawn) The method of claim 39, wherein the host is a mammal.

52. (Withdrawn) The method of claim 39, wherein the host is a human.

53. (Withdrawn) A method for treating a host infected with a *coronavirus*, herpes virus or *togavirus*, comprising administering an anti-viral effective amount of a compound, or a pharmaceutically acceptable salt or prodrug thereof, having a structure of Formula AA-1:

(AA-1)



wherein:

X^1 is —NHC(O)—;

X^2 is —O—;

R^1 is —C_1-C_{22} alkyl;

R^2 is —C_1-C_{22} alkyl;

R^6 is —CH_2CH_2; and

R^3, R^4 and R^5 are methyl.

54. (Withdrawn) The method of claim 53, wherein:

R^1 is —CH_3, —CH_2CH_3, —$CH_2CH_2CH_3$, —$CH_2CH_2CH_2CH_3$, —$CH_2CH_2CH_2CH_2CH_3$, —$(CH_2)_5CH_3$, —$(CH_2)_6CH_3$, —$(CH_2)_7CH_3$, —$(CH_2)_8CH_3$, —$(CH_2)_9CH_3$, —$(CH_2)_{10}CH_3$, —$(CH_2)_{11}CH_3$, —$(CH_2)_{12}CH_3$ or —$(CH_2)_{13}CH_3$; and R^2 is —CH_3, —$CH_{22}CH_3$, —$CH_2CH_2CH_2CH_3$, —$CH_2CH_2CH_2CH_2CH_3$, —$(CH_2)_5CH_3$, —$(CH_2)_6CH_3$, —$(CH_2)_7CH_3$, —$(CH_2)_8CH_3$, —$(CH_2)_9CH_3$, —$(CH_2)_{10}CH_3$, —$(CH_2)_{11}CH_3$, —$(CH_2)_{12}CH_3$ or —$(CH_2)_{13}CH_3$.

55. (Withdrawn) The method of claim 53, wherein the host is infected with a *coronavirus*.

56. (Withdrawn) The method of claim 55, wherein the *coronavirus* is SARS-CoV.

57. (Withdrawn) The method of claim 56, wherein:

R^1 is —$(CH_2)_9CH_3$- , —$(CH_2)_{10}CH_3$, or —$(CH_2)_{11}CH_3$; and

R^2 is —$CH_2CH_2CH_3$, —$CH_2CH_2CH_2CH_3$, or —$CH_2(CH_2)_3CH_3$.

58. (Withdrawn) The method of claim 56, wherein the compound is:



59. (Withdrawn) The method of claim 53, wherein the host is infected with a herpes virus.

60. (Withdrawn) The method of claim 59, wherein the herpes virus is varicella zoster virus.

61. (Withdrawn) The method of claim 60, wherein: R^1 is —$(CH_2)_7CH_3$- , —$(CH_2)_8CH_3$, or —$(CH_2)_9CH_3$; R^2 is —$(CH_2)_9CH_3$, —$(CH_2)_{10}CH_3$, or —$(CH_2)_{11}CH_3$;

62. (Withdrawn) The method of claim 60, wherein the compound is:



63. (Withdrawn) The method of claim 59, wherein the herpes virus is *cytomegalovirus*.

64. (Withdrawn) The method of claim 1, wherein the virus is a *togavirus*.

65. (Previously presented) The method of claim 1, wherein the compound is administered orally, by inhalation, intravenously, parenterally, intradermally, subcutaneously or topically.